CN103006730A - Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease - Google Patents
Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease Download PDFInfo
- Publication number
- CN103006730A CN103006730A CN2012105849063A CN201210584906A CN103006730A CN 103006730 A CN103006730 A CN 103006730A CN 2012105849063 A CN2012105849063 A CN 2012105849063A CN 201210584906 A CN201210584906 A CN 201210584906A CN 103006730 A CN103006730 A CN 103006730A
- Authority
- CN
- China
- Prior art keywords
- nitric oxide
- arginine
- vitamin
- arasaponin
- cardiovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 239000004475 Arginine Substances 0.000 title claims abstract description 58
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 44
- 230000001737 promoting effect Effects 0.000 title abstract description 4
- 239000009277 Panax notoginseng extract Substances 0.000 title abstract 2
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 60
- 241000180649 Panax notoginseng Species 0.000 claims description 60
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 52
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 52
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 52
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 52
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 34
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 34
- 229960002173 citrulline Drugs 0.000 claims description 34
- 235000013477 citrulline Nutrition 0.000 claims description 34
- 230000004224 protection Effects 0.000 claims description 33
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 26
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 26
- 229930003268 Vitamin C Natural products 0.000 claims description 26
- 229930003427 Vitamin E Natural products 0.000 claims description 26
- 235000019152 folic acid Nutrition 0.000 claims description 26
- 229960000304 folic acid Drugs 0.000 claims description 26
- 239000011724 folic acid Substances 0.000 claims description 26
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 26
- 229960003080 taurine Drugs 0.000 claims description 26
- 235000019154 vitamin C Nutrition 0.000 claims description 26
- 239000011718 vitamin C Substances 0.000 claims description 26
- 235000019165 vitamin E Nutrition 0.000 claims description 26
- 229940046009 vitamin E Drugs 0.000 claims description 26
- 239000011709 vitamin E Substances 0.000 claims description 26
- 150000004676 glycans Chemical class 0.000 claims description 18
- 229920001282 polysaccharide Polymers 0.000 claims description 18
- 239000005017 polysaccharide Substances 0.000 claims description 18
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 14
- 229930003944 flavone Natural products 0.000 claims description 14
- 150000002212 flavone derivatives Chemical class 0.000 claims description 14
- 235000011949 flavones Nutrition 0.000 claims description 14
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 14
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 10
- 230000002265 prevention Effects 0.000 abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 5
- 230000036770 blood supply Effects 0.000 abstract description 2
- 229960003121 arginine Drugs 0.000 description 47
- 235000009697 arginine Nutrition 0.000 description 46
- 229960003753 nitric oxide Drugs 0.000 description 29
- 239000000047 product Substances 0.000 description 26
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 20
- 229930182490 saponin Natural products 0.000 description 20
- 150000007949 saponins Chemical class 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 15
- 239000007902 hard capsule Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 229930064664 L-arginine Natural products 0.000 description 11
- 235000014852 L-arginine Nutrition 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- -1 fatty acid ester Chemical class 0.000 description 7
- 229930182494 ginsenoside Natural products 0.000 description 7
- 229940089161 ginsenoside Drugs 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000037353 metabolic pathway Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010018873 Haemoconcentration Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 3
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960003589 arginine hydrochloride Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WKVZMKDXJFCMMD-UVWUDEKDSA-L (5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one;azanide;n,3-bis(2-chloroethyl)-2-ox Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.ClCCNP1(=O)OCCCN1CCCl.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 WKVZMKDXJFCMMD-UVWUDEKDSA-L 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102100032252 Antizyme inhibitor 2 Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000798222 Homo sapiens Antizyme inhibitor 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008799 immune stress Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940124280 l-arginine Drugs 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a composition containing arginine and a panax notoginseng extract for promoting nitric oxide generation and preventing and protecting a cardiovascular disease. The composition can inhibit urea nitrogen, removes free radicals, keeps nitrogen balance, promotes the nitric oxide generation to improve tissue blood supply to the greatest extent, reduces platelet adhesion activity, and can be applied to the prevention and treatment of the cardiovascular disease effectively.
Description
Technical field
The present invention relates to promote the compositions that is used for cardiovascular diseases's protection of nitric oxide generation, can effectively be used for prevention and the rehabilitation that the cardiovascular diseases protect disease.
Background technology
Arginine is a kind of basic amino acid, and decomposition and endogenous that the arginine of human body derives from diet, body protein generate three parts.Normally the about 5g of arginine intake in diet every day contains abundant arginine in fish and the nut.Thought in the past that arginine was non essential amino acid, but when some special disease such as sepsis, its quantity can not satisfy the demand of body, so be referred to as again conditionally essential amino acid.Common to have the L-arginine (L-Arginine of physiologically active in the body, L-Arg) form is brought into play its biological function, its metabolism mainly contains two kinds of approach: the one, directly or indirectly participate in ornithine cycle, namely under the arginase effect, be decomposed into ornithine and carbamide, play a significant role in the During Detoxification of the ammonia that produces in vivo; The 2nd, participate in body Arg/NO approach, namely under nitricoxide synthase (NOS) effect, be decomposed into equimolecular citrulline and NO.Wherein NO is a kind of vascular relaxing factor, can cause smooth muscle loosening, vasodilation, Blood pressure drop and anticoagulant, adhesion by acting on cGMP (guanylate cyclase).
For the first metabolic pathway, (the p H-number of (chemical name is the L-Arginine hydrochlorate) medicine own is 3.0～5.0 to arginine hydrochloride, utilize just clinically the acidity treatment metabolic alkalosis of arginine hydrochloride solution, and administering mode all is intravenous drip.
For the second metabolic pathway, therefore, arginine is transformed into NO by the L-Arg/NO metabolic pathway, plays very important effect to preventing and treating a series of cardiovascular disease such as hypertension, atherosclerosis.Scientific Articles has been reported, its physiological action of arginine comprises, the vasodilation (" Journal of the American College of Cardiology " that is caused by oral absorption arginine, " American Journal of Cardiology ", 2000, vol.35, p.706-713), suppress hypertension (" Laboratory Investigation y ", " laboratory research ", 1993, vol.68, p.174-184), sexual function improves " non-BJU International ", " Britain international standard urology magazine ", 1999, vol.83, p.269-273) etc.Therefore, arginine has been used to promote medicine, the functional food of nitric oxide generation, and is used for treatment and health care that the cardiovascular diseases protects patient, and its occupation mode all is that employing is oral, and dosage form is solid preparation.
Modern study finds that hepatic and kidney function obstacle even liver and kidney failure often appear in the old cardiovascular disease patient, and long-term excessive use arginine may increase the weight of the Liver and kidney burden.This moment, body participated in arginase and the active decline of arginine decarboxylase of arginine metabolism, rise and nitricoxide synthase (NOS) is active, the arginine that replenishes may cause body to produce too much nitric oxide (NO), cause primary cellular defect and immunological stress, be unfavorable for the maintenance machine homoiostasis.Domestic research has been found that: L-arginine blood urea nitrogen obviously raise (curative effect and the safety pre-test of aged patients with chronic heart failure " L-arginine treatment " occurs at the treatment aged patients with chronic heart failure, " Sichuan medical science ", in July, 2004, the 25th volume, the 7th phase)).Therefore, Canadian nutritional guidelines do not recommend critical patient to use arginine, especially pyemic non-surgical patients (" progress that arginine metabolism changes and uses in the sepsis ", " Guangdong medical science ", in June, 2009, the 30th volume, the 6th phase).
Therefore, arginine is conditionally essential amino acid, and with regard to the second metabolic pathway, the NO of low dosage has the Tissue Blood of improvement and supplies, reduces platelet adhesion reaction, suppresses inflammatory reaction, promotes the beneficial effects such as protein synthesis and acceleration wound repair.And the NO of high dose can induce to produce a large amount of inflammatory mediators and free radical in immune cell activated, promotes inflammatory reaction, increases the weight of tissue injury.
For the old cardiovascular disease patient, the multiformity of Effect of Nitric Oxide makes on disease prevention and the clinical treatment arginine have " double-edged sword " effect, use and appropriately can improve therapeutic effect, improper use, increase the weight of on the contrary infringement, run counter to desire, therefore, on disease prevention and the clinical treatment, need when in use to adopt specific material to suppress a large amount of generations of inflammatory mediator and free radical, suppress blood urea nitrogen, keep nitrogen balance, keep simultaneously the nitric oxide production vigor that Tissue Blood supplies, reduces platelet adhesion reaction that improves.
Technical scheme
The purpose of this invention is to provide for the compositions that is used for cardiovascular diseases's protection that promotes that nitric oxide generates, it can be used for prevention and the rehabilitation that the cardiovascular diseases protects disease effectively, can suppress blood urea nitrogen, keeps nitrogen balance.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng extract.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng extract, citrulline.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng extract, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng flavone, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng polysaccharide, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin, Radix Notoginseng flavone, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin, Radix Notoginseng polysaccharide, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin, Radix Notoginseng flavone, Radix Notoginseng polysaccharide, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin R1, Ginsenoside Rg1, Panax Notoginseng saponin R d, Panax Notoginseng saponin R e, arasaponin b1, arasaponin E, arasaponin H, arasaponin M, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin R1, Ginsenoside Rg1, Panax Notoginseng saponin R d, Panax Notoginseng saponin R e, arasaponin b1, arasaponin E, arasaponin H, arasaponin M, Radix Notoginseng flavone, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin R1, Ginsenoside Rg1, Panax Notoginseng saponin R d, Panax Notoginseng saponin R e, arasaponin b1, arasaponin E, arasaponin H, arasaponin M, Radix Notoginseng polysaccharide, citrulline, taurine, vitamin C, vitamin E, folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2-10g arginine, 2.5-10mg arasaponin R1,0.5-10mg Ginsenoside Rg1,0.5-10mg Panax Notoginseng saponin R d, 0.1-10mg Panax Notoginseng saponin R e, 0.1-10mg arasaponin b1,200-1000mg Radix Notoginseng polysaccharide, 0.5-10g citrulline, 2.8-10g taurine, 2.6-10g vitamin C, 0.6-10g vitamin E, 2.5-10mg folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2-10g arginine, 2.5-10mg arasaponin R1,0.5-10mg Ginsenoside Rg1,0.5-10mg Panax Notoginseng saponin R d, 0.1-10mg Panax Notoginseng saponin R e, 0.1-10mg arasaponin b1,0.1-10mg arasaponin E, 0.1-10mg arasaponin H, 0.1-10mg arasaponin M, 200-1000mg Radix Notoginseng polysaccharide, 0.5-10g citrulline, 2.8-10g taurine, 2.6-10g vitamin C, 0.6-10g vitamin E, 2.5-10mg folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2-10g arginine, 1-10mg Radix Notoginseng flavone, 200-1000mg Radix Notoginseng polysaccharide, 0.5-10g citrulline, 2.8-10g taurine, 2.6-10g vitamin C, 0.6-10g vitamin E, 2.5-10mg folic acid.
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2-10g arginine, 2.5-10mg arasaponin R1,0.5-10mg Ginsenoside Rg1,0.5-10mg Panax Notoginseng saponin R d, 0.1-10mg Panax Notoginseng saponin R e, 0.1-10mg arasaponin b1,0.1-10mg arasaponin E, 0.1-10mg arasaponin H, 0.1-10mg arasaponin M, 1-10mg Radix Notoginseng flavone, 200-1000mg Radix Notoginseng polysaccharide, 0.5-10g citrulline, 2.8-10g taurine, 2.6-10g vitamin C, 0.6-10g vitamin E, 2.5-10mg folic acid.
The citrulline that uses among the present invention and arginine can be any forms in L-type, D-type and the DL-type, preferred L-type.
The dosage form of oral formulations of the present invention: comprise tablet, powder, granule, emulsion, syrup, capsule etc., be preferably powder, tablet and granule.
The additive of oral formulations of the present invention comprises: excipient, adhesive, disintegrating agent, lubricant, dispersant, suspending agent, emulsifying agent, diluent, buffer agent, antioxidant, antibacterial, correctives, spice, coloring agent etc.
Excipient can add saccharide such as lactose, white sugar, glucose, sucrose, mannitol, Sorbitol etc., starch such as Rhizoma Solani tuber osi, Semen Tritici aestivi, Semen Maydis etc., inorganic matter such as calcium carbonate, calcium sulfate, sodium bicarbonate, sodium chloride etc., plant powder (Radix Glycyrrhizae, HUANGLONG gallbladder powder etc.) etc.
Disintegrating agent such as starch, agar, jelly powder, crystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, calcium carbonate, sodium bicarbonate, sodium alginate etc.,
Lubricant such as magnesium stearate, Pulvis Talci, hydrogenated vegetable oil, Polyethylene Glycol, silicone oil etc.,
Adhesive such as polyvinyl alcohol, hydroxypropyl cellulose, methylcellulose, ethyl cellulose, carboxymethyl cellulose, gelatin, amylan solution etc.,
Surfactant such as fatty acid ester etc., plasticizer such as glycerol etc.
Spice such as strawberry flavor, Herba Menthae etc.
Dosage form of the present invention is box-packed or nested form.
Dosage form of the present invention is oral formulations,
Product of the present invention, it is used for the preparation of the medicine of following purposes:
Product of the present invention, it is used for promoting blood flow.
Product of the present invention, it is used for prevention or improves by blood flow and reduce the symptom that causes.
Product of the present invention, it is used for reducing the symptom that causes by blood flow and is: shoulder is stiff, be afraid of cold, at least a symptom of erection disturbance.
Product of the present invention, it is used for suppressing blood ammonia levels and improves.
Product of the present invention, it is used for suppressing blood urea nitrogen, removes free radical, keeps nitrogen balance.
Product of the present invention, it is used for strengthening anoxia enduring and anti-fatigue ability.
Product of the present invention, it is used for prevention and rehabilitation that the cardiovascular diseases protects disease.
Product of the present invention, it is for reducing blood pressure.
The invention effect
Because the present invention is promoting blood flow effectively, safety improves, and effectively prevents the generation of side effect symptom.
Although oral formulations of the present invention be used for to be taken in or the dosage of administration and age that administration frequency depends on form of medication, administration object, body weight etc. and change, but the total amount of citrulline or its salt and arginine or its salt, for adult every day, in free citrulline and arginine, be generally 2mg～20g, be preferably 2mg～10g, be particularly preferably 200mg～5g, generally arrive once a day a minute several times administration.In addition, although administration time is not specifically limited, be generally 1 day～1 year, be preferably 1 week～3 month.
Because the present invention has adopted the compound preparation of arginine and Radix Notoginseng extract, the consumption that has reduced the adult of free citrulline and arginine meter to prevent the Liver and kidney burden that is caused by long-term excessive use arginine.
Radix Notoginseng polysaccharide, Radix Notoginseng flavone, arasaponin that the present invention adopts prepare according to the ordinary skill in the art, can effectively reduce the use of additive, provide cost savings, than the product that does not adopt Radix Notoginseng polysaccharide, Radix Notoginseng flavone, product of the present invention has improved the stability of preparation, shelf-life has prolonged 35%, and the stability of citrulline, arginine, arasaponin has strengthened 25%, is not easy to decompose.
The specific embodiment
Specific embodiment 1
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2g arginine, 2.5mg arasaponin R1,0.5mg Ginsenoside Rg1,0.5mg Panax Notoginseng saponin R d, 0.1mg Panax Notoginseng saponin R e, 0.1mg arasaponin b1,200mg Radix Notoginseng polysaccharide, 0.5g citrulline, 2.8g taurine, 2.6g vitamin C, 0.6g vitamin E, 2.5mg folic acid.
With above powder 100g, mix with sucrose fatty acid ester 5g, calcium phosphate 2g, silicon dioxide 0.2g and stir, drying, sterilization, both.
The mixture that can also just obtain is filled in the hard capsules to make hard capsule.
The surface of hard capsule corn protein solution coating is made enteric coated capsule.
The mixture tabletting that can also just obtain.
Specific embodiment 2
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2g arginine, 1mg Radix Notoginseng flavone, 200mg Radix Notoginseng polysaccharide, 0.5g citrulline, 2.8g taurine, 2.6g vitamin C, 0.6g vitamin E, 2.5mg folic acid.
With above powder 100g, mix with sucrose fatty acid ester 5g, calcium phosphate 2g, silicon dioxide 0.2g and stir, drying, sterilization, both.
The mixture that can also just obtain is filled in the hard capsules to make hard capsule.
The surface of hard capsule corn protein solution coating is made enteric coated capsule.
The mixture tabletting that can also just obtain.
Specific embodiment 3
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2g arginine, 2.5mg arasaponin R1,0.5mg Ginsenoside Rg1,0.5mg Panax Notoginseng saponin R d, 0.1mg Panax Notoginseng saponin R e, 0.1mg arasaponin b1,0.1mg arasaponin E, 0.1mg arasaponin H, 0.1mg arasaponin M, 1mg Radix Notoginseng flavone, 200mg Radix Notoginseng polysaccharide, 0.5g citrulline, 2.8g taurine, 2.6g vitamin C, 0.6g vitamin E, 2.5mg folic acid.
With above powder 100g, mix with sucrose fatty acid ester 5g, calcium phosphate 2g, silicon dioxide 0.2g and stir, drying, sterilization, both.
The mixture that can also just obtain is filled in the hard capsules to make hard capsule.
The surface of hard capsule corn protein solution coating is made enteric coated capsule.
The mixture tabletting that can also just obtain.
Specific embodiment 4
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2g arginine, 2.5mg arasaponin R1,0.5mg Ginsenoside Rg1,0.5mg Panax Notoginseng saponin R d, 0.1mg Panax Notoginseng saponin R e, 0.1mg arasaponin b1,0.1mg arasaponin E, 0.1mg arasaponin H, 0.1mg arasaponin M, 200mg Radix Notoginseng polysaccharide, 0.5g citrulline, 2.8g taurine, 2.6g vitamin C, 0.6g vitamin E, 2.5mg folic acid.
With above powder 100g, mix with sucrose fatty acid ester 5g, calcium phosphate 2g, silicon dioxide 0.2g and stir, drying, sterilization, both.
The mixture that can also just obtain is filled in the hard capsules to make hard capsule.
The surface of hard capsule corn protein solution coating is made enteric coated capsule.
The mixture tabletting that can also just obtain.
Specific embodiment 5
Promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain: contain 2g arginine, 2.5mg arasaponin R1,0.5mg Ginsenoside Rg1,0.5mg Panax Notoginseng saponin R d, 0.1mg Panax Notoginseng saponin R e, 0.1mg arasaponin b1,0.1mg arasaponin E, 0.1mg arasaponin H, 0.1mg arasaponin M, 1mg Radix Notoginseng flavone, 200mg Radix Notoginseng polysaccharide, 0.5g citrulline, 2.8g taurine, 2.6g vitamin C, 0.6g vitamin E, 2.5mg folic acid.
With above powder 100g, mix with sucrose fatty acid ester 5g, calcium phosphate 2g, silicon dioxide 0.2g and stir, drying, sterilization, both.
The mixture that can also just obtain is filled in the hard capsules to make hard capsule.
The surface of hard capsule corn protein solution coating is made enteric coated capsule.
The mixture tabletting that can also just obtain.
Specific embodiment 6
Normal group: get 10 10 the week male SD normal rats in age (220-240 gram), with catheter retaining in the jugular vein of normal rat.
Model group: 50 10 the week male SD in age (220-240 gram) set up isoproterenol induce the treating myocardial ischemia damage model (＜isoproterenol is induced the progress for the treatment of myocardial ischemia damage model 〉,＜Medical review 〉, 23 phases in 2010).With catheter retaining in the jugular vein of rat model.
Rat model and normal rat were all raised 3 days in advance, and average mark in groups.
Under fasted conditions not, give the 1st group of normal rat Oral L-arginine, 400mg/kg.
Under fasted conditions not, give the 2nd group model Oral Administration in Rats L-arginine, 400mg/kg.
Under fasted conditions not, give simultaneously Oral L-arginine+Cit of the 3rd group model rat, wherein L-arginine and Cit are 400mg/kg and 100mg/kg after converting.
Give the powder that does not contain pharmaceutical adjunct of 4-6 group model Oral Administration in Rats specific embodiment 1-3, wherein L-arginine and Cit are 400mg/kg and 100mg/kg after converting.
Before taking medicine, and took medicine rear 30 minutes, 1,2,4,8 hour, collect blood from jugular vein.Blood collecting is contained therein in the 1.5mL pipe of 1% heparin of prior distribution, and centrifugal (12000rpm, 10min, 4 ℃) are to obtain blood plasma.Then, add with 3% sulfosalicylic acid of the same amount of blood plasma and also mix, mixture was left standstill on ice 1 hour and centrifugal (12000rpm, 10min, 4 ℃), to give Deproteinated blood plasma as sample for analysis.The content of the L-arginine of the sample of be used for analyzing.
Before taking medicine, and took medicine rear 30 minutes, 1,2,4,8 hour, collect urine, detect the content of blood urea nitrogen.
After 8 hours, with by the ventral aorta blood drawing, divide 2 pipes to collect respectively blood plasma and serum.All rat is put to death, and opens breast, wins heart, and flush away bloodstain in 4 ℃ of normal saline blots excessive moisture, the weighing cardiac mass.The heart of doing pathology is put into 4% paraformaldehyde and is fixed; Downcut part left ventricle antetheca cardiac muscle, added normal saline by weight 1: 9 and prepare 10% homogenate, 3000r/min, 4 ℃ of centrifugal supernatants that go are to be measured.Survey superoxide dismutase (SOD), malonaldehyde (MDA), Total antioxidant capacity (T-AOC).
Interpretation of result:
Given the product of specific embodiment 1-3 in the 4-6 group, compared with the 3rd group with the 2nd group,
Arginic maximum drug level (C
Max) significantly improve.The remarkable increase of area under arginic haemoconcentration-time graph.
Maximum drug level (the C of blood urea nitrogen
Max) significantly reduce and maximum drug level time (T
Max) shorten.Area significantly dwindles under the haemoconcentration-time graph of blood urea nitrogen.
Give the product of specific embodiment 1-3 in the 4-6 group, compared the maximum drug level (C of blood urea nitrogen with the 1st group
Max) obviously do not raise, area does not obviously raise under the haemoconcentration-time graph of blood urea nitrogen.
This experiment shows, but product Effective Raise blood-arginine-level of the present invention, the prevention blood ammonia levels caused various different symptoms that raises.
The variation of arginine concentration
The variation of urea nitrogen concentration
The product of specific embodiment 1-3 causes the impact of Acute Myocardial Ischemia Rats cardiac index on ISO
| Grouping | X±S |
| The 1st group | 0.31±0.03 |
| The 2nd group | 0.43±0.08 |
| The 3rd group | 0.44±0.07 |
| The 4th group | 0.36±0.09 |
| The 5th group | 0.37±0.06 |
| The 6th group | 0.35±0.05 |
With the 1st group of comparison, the group of products cardiac index of 2-3 group and specific embodiment 1-3 all significantly increases (P＜0.05 or P＜0.01); Compare with the 2-3 group, the group of products cardiac index of specific embodiment 1-3 decreases.This experiment shows that product of the present invention is cardioprotection effectively.
ISO is caused the impact of Acute Myocardial Ischemia Rats myocardium lipid peroxidation
The product of specific embodiment 1-3 is on the impact of the SOD of cardiac muscular tissue, MDA and T-AOC value
| Grouping | SOD | MDA | T-AOC |
| ? | U/ml | nmol/ml | U/ml |
| The 1st group | 312.37±10.21 | 1.37±0.59 | 21.32±2.54 |
| The 2nd group | 243.23±23.82 | 3.19±0.54 | 17.32±3.36 |
| The 3rd group | 226.74±24.53 | 3.48±0.13 | 19.46±0.21 |
| The 4th group | 289.53±29.34 | 2.19±0.39 | 11.12±0.56 |
| The 5th group | 291.36±30.12 | 2.37±0.24 | 12.31±0.26 |
| The 6th group | 286.53±41.26 | 2.41±0.26 | 11.45±0.37 |
The group of products of model and specific embodiment 1-3
With the 1st group of comparison, the remarkable rising of 2-3 group MDA value, SOD, T-AOC value significantly reduce (P＜0.05 or P＜0.01); Compare with the 2-3 group, the group of products MDA value of specific embodiment 1-3 significantly reduces (P＜0.05), the group of products SOD value of specific embodiment 1-3 significantly raises (P＜0.05), and the group of products T-AOC value of specific embodiment 1-3 has rising trend significantly raise (P＜0.05).The experimental result explanation: the product of specific embodiment 1-3 significantly strengthens myocardium oxidation resistance by after the reasonable compatibility medication, improves the SOD of heart tissue enzymatic activity, and the oxygen free radical injury that ischemia resisting is caused has repair.
Specific embodiment 10
20 hypertensive patients, age 46-72 year, be equally divided into 2 groups, no significant difference between group,
Instructions of taking: with specific embodiment 3 products, wash decoction being taken warmly open with 100～150ml boiling water.Every day 3 times, each 5 grams,
Matched group is taken QUANTIANMA JIAONANG, every day 3 times, each 3.
Two groups all do not add other depressor during the treatment.
The result
Curative effect is judged
Efficacy of antihypertensive treatment: judge according to the curative effect of medication index that in July, 1993, bureau of drug administration of Ministry of Health of the People's Republic of China formulated.
Produce effects: systolic pressure decline 〉=10mmHg also is down to normal; Or diastolic pressure decline 〉=20mmHg;
Effectively: though systolic pressure descend do not reach 〉=10mmHg is down to normally; Or diastolic pressure decline 〉=10～19mmHg;
Invalid: as not reach above-mentioned standard.
Blood pressure result before and after treatment group and the treatment of control group (X ± S)
Conclusion: product of the present invention can suppress blood urea nitrogen, has removed free radical, has kept nitrogen balance, and the greatly nitric oxide production vigor that improves the Tissue Blood confession, reduces platelet adhesion reaction can be effectively used to prevention and rehabilitation that the cardiovascular diseases protects disease.
Claims (9)
1. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng extract.
2. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng extract, citrulline.
3. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng extract, citrulline, taurine, vitamin C, vitamin E, folic acid.
4. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin, citrulline, taurine, vitamin C, vitamin E, folic acid.
5. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng flavone, citrulline, taurine, vitamin C, vitamin E, folic acid.
6. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, Radix Notoginseng polysaccharide, citrulline, taurine, vitamin C, vitamin E, folic acid.
7. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin, Radix Notoginseng flavone, citrulline, taurine, vitamin C, vitamin E, folic acid.
8. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin, Radix Notoginseng polysaccharide, citrulline, taurine, vitamin C, vitamin E, folic acid.
9. promote the compositions that is used for cardiovascular diseases's protection that nitric oxide generates, contain arginine, arasaponin, Radix Notoginseng flavone, Radix Notoginseng polysaccharide, citrulline, taurine, vitamin C, vitamin E, folic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210584906.3A CN103006730B (en) | 2012-12-31 | 2012-12-31 | Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210584906.3A CN103006730B (en) | 2012-12-31 | 2012-12-31 | Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103006730A true CN103006730A (en) | 2013-04-03 |
| CN103006730B CN103006730B (en) | 2014-06-18 |
Family
ID=47956193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210584906.3A Expired - Fee Related CN103006730B (en) | 2012-12-31 | 2012-12-31 | Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103006730B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263018A (en) * | 2013-04-27 | 2013-08-28 | 北京中国科学院老专家技术中心 | Nitric oxide functional beverage and preparation method thereof |
| CN104256623A (en) * | 2014-10-22 | 2015-01-07 | 何瑞红 | Composition for conditioning health of patient suffering from hypertension, hyperlipidemia and hyperglycemia, and preparation method and application of composition |
| CN105012371A (en) * | 2015-06-09 | 2015-11-04 | 段胜保 | Antihypertensive drug for preventing, treating and reversing primary hypertension disease and application |
| CN105878282A (en) * | 2016-05-14 | 2016-08-24 | 张恒洲 | Health care product with compatibility of bezoar and nitric oxide, and preparation method thereof |
| CN109645494A (en) * | 2019-01-23 | 2019-04-19 | 四川治宇东盟贸易有限责任公司 | Improve function of human body and prevents the composition and preparation method of cardiovascular and cerebrovascular disease |
| CN109998117A (en) * | 2019-04-15 | 2019-07-12 | 云南菌沃生物技术有限公司 | Improve the integration of drinking and medicinal herbs food and preparation method and application of blood pressure |
| CN112370521A (en) * | 2020-12-24 | 2021-02-19 | 无锡瑞年聚元堂国医馆有限公司 | Chinese and western medicine composition for promoting blood circulation to remove blood stasis and eliminating soft and hard plaque of artery and preparation method and application thereof |
| CN115192595A (en) * | 2022-07-25 | 2022-10-18 | 昆明医科大学第一附属医院 | Application of notoginsenoside Rd in pharmacy |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726902A (en) * | 2005-07-26 | 2006-02-01 | 钟健琳 | Combined formula and application of agent for stimulating growth of hair, and application |
| CN1762440A (en) * | 2004-10-18 | 2006-04-26 | 沈津湛 | Medicine for preventing and treating cardiovascular and cerebrovascular diseases |
| CN1763163A (en) * | 2005-10-25 | 2006-04-26 | 孙天民 | Nutritional red wine and preparation process thereof |
| CN101618044A (en) * | 2008-07-02 | 2010-01-06 | 丽珠医药集团股份有限公司 | Contain ginsenoside, arasaponin and amino acid whose capsule and preparation method thereof |
| CN101933972A (en) * | 2010-08-20 | 2011-01-05 | 王亭 | Nitric oxide reinforcing agent and application thereof |
-
2012
- 2012-12-31 CN CN201210584906.3A patent/CN103006730B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1762440A (en) * | 2004-10-18 | 2006-04-26 | 沈津湛 | Medicine for preventing and treating cardiovascular and cerebrovascular diseases |
| CN1726902A (en) * | 2005-07-26 | 2006-02-01 | 钟健琳 | Combined formula and application of agent for stimulating growth of hair, and application |
| CN1763163A (en) * | 2005-10-25 | 2006-04-26 | 孙天民 | Nutritional red wine and preparation process thereof |
| CN101618044A (en) * | 2008-07-02 | 2010-01-06 | 丽珠医药集团股份有限公司 | Contain ginsenoside, arasaponin and amino acid whose capsule and preparation method thereof |
| CN101933972A (en) * | 2010-08-20 | 2011-01-05 | 王亭 | Nitric oxide reinforcing agent and application thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263018A (en) * | 2013-04-27 | 2013-08-28 | 北京中国科学院老专家技术中心 | Nitric oxide functional beverage and preparation method thereof |
| CN104256623A (en) * | 2014-10-22 | 2015-01-07 | 何瑞红 | Composition for conditioning health of patient suffering from hypertension, hyperlipidemia and hyperglycemia, and preparation method and application of composition |
| CN105012371A (en) * | 2015-06-09 | 2015-11-04 | 段胜保 | Antihypertensive drug for preventing, treating and reversing primary hypertension disease and application |
| CN105878282A (en) * | 2016-05-14 | 2016-08-24 | 张恒洲 | Health care product with compatibility of bezoar and nitric oxide, and preparation method thereof |
| CN109645494A (en) * | 2019-01-23 | 2019-04-19 | 四川治宇东盟贸易有限责任公司 | Improve function of human body and prevents the composition and preparation method of cardiovascular and cerebrovascular disease |
| CN109998117A (en) * | 2019-04-15 | 2019-07-12 | 云南菌沃生物技术有限公司 | Improve the integration of drinking and medicinal herbs food and preparation method and application of blood pressure |
| CN112370521A (en) * | 2020-12-24 | 2021-02-19 | 无锡瑞年聚元堂国医馆有限公司 | Chinese and western medicine composition for promoting blood circulation to remove blood stasis and eliminating soft and hard plaque of artery and preparation method and application thereof |
| CN115192595A (en) * | 2022-07-25 | 2022-10-18 | 昆明医科大学第一附属医院 | Application of notoginsenoside Rd in pharmacy |
| CN115192595B (en) * | 2022-07-25 | 2023-08-22 | 昆明医科大学第一附属医院 | Application of notoginsenoside Rd in pharmacy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103006730B (en) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006730B (en) | Composition containing arginine and panax notoginseng extract for promoting nitric oxide generation and preventing and protecting cardiovascular disease | |
| US20030004215A1 (en) | Dietetic preparation and method for inhibiting intestinal carbohydrate absorption | |
| EP2512236A1 (en) | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
| KR20130131303A (en) | Anti-fatigue composition, formulation and use thereof | |
| CN103007098B (en) | Composition with functions of accelerating generation of nitric oxide and improving immunity and containing arginine, ginseng and coix seeds | |
| JP5935204B2 (en) | Osteoporosis preventive or ameliorating agent | |
| CN101108227A (en) | Konjak extractive powder capsule | |
| CN104955468A (en) | Nitric oxide concentration elevating agent | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN108066712A (en) | A kind of benefiting qi and nourishing blood Chinese medicine composition | |
| CN106692532A (en) | Traditional Chinese medicine composition used for burning fat and losing weight as well as patch and weight losing package thereof | |
| KR100949482B1 (en) | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| CN103505612A (en) | Traditional Chinese medicine composition containing total flavonoids of sea-buckthorn and preparation method of composition | |
| CN104606670A (en) | Medicine for treating cardiovascular disease | |
| KR100964603B1 (en) | Phamaceutical composition of diabetes mellitus using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| CN108355055A (en) | A kind of pharmaceutical composition for treating hypertension | |
| CN107184598A (en) | A kind of pet heart disease composite tablet | |
| CN103478703A (en) | Health food with fatigue resistance function and preparation method thereof | |
| CN114848699A (en) | Composition with effect of reducing uric acid and preparation method and application thereof | |
| JP2023522579A (en) | Composition containing fiber and mulberry | |
| CN102488049A (en) | Rhodiola coffee | |
| CN108433106A (en) | A kind of Oxygen-deficient endurance fructose powder (liquid) composition | |
| CN110935002A (en) | Composition with blood pressure lowering effect and application thereof | |
| CN108850377A (en) | A kind of natural traditional Chinese medicine health preserving tea and preparation method thereof | |
| KR101297034B1 (en) | Composition for preventing and treating metabolic syndrome comprising eel extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ding Jiayi Inventor after: Pan Ke Inventor after: Zhao Mingqiang Inventor before: Zhang Yihua Inventor before: Ding Jiayi Inventor before: Pan Ke Inventor before: Zhao Mingqiang |
|
| ASS | Succession or assignment of patent right |
Owner name: YANGZHOU DINGJIAYI AGRICULTURAL TECHNOLOGY CO., LT Free format text: FORMER OWNER: DING JIAYI Effective date: 20140508 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 225009 YANGZHOU, JIANGSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140508 Address after: 225009 A1 building, Yangzhou science and Technology Park, Xi'an Jiao Tong University, 198 East 501 Wu Road, Yangzhou Development Zone, Jiangsu, China Applicant after: Yangzhou Dingjiayi Agricultural Technology Co.,Ltd. Address before: 210009, room 2, unit 5, building 40, 202 Ma Ka street, Jiangsu, Nanjing Applicant before: Ding Jiayi |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TJOY HEALTH TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: YANGZHOU DINGJIAYI AGRICULTURAL TECHNOLOGY CO., LTD. Effective date: 20141016 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20141016 Address after: 2, Building 102, building 198, 225009 east Wu Chau Road, Yangzhou, Jiangsu Patentee after: TJOY HEALTH TECHNOLOGY CO., LTD. Address before: 225009 A1 building, Yangzhou science and Technology Park, Xi'an Jiao Tong University, 198 East 501 Wu Road, Yangzhou Development Zone, Jiangsu, China Patentee before: Yangzhou Dingjiayi Agricultural Technology Co.,Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: TJOY HEALTH TECHNOLOGY CO., LTD. Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: TJOY HEALTH TECHNOLOGY CO., LTD. Document name: Notification of Termination of Patent Right |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140618 Termination date: 20181231 |